Kenneth J. Kelley, Director at HALOZYME THERAPEUTICS INC (HTI), sold 24,500 shares at $8.33 ($205K) on 2007-03-27, disclosed to the SEC on 2007-03-28.
Scheduled sale ($205k) by Director under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Negative factors outweigh the positive ones.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $8.33 | 300 | $2K | 1.2% |
| 2 | $8.34 | 1,000 | $8K | 4.1% |
| 3 | $8.35 | 1,154 | $10K | 4.7% |
| 4 | $8.36 | 290 | $2K | 1.2% |
| 5 | $8.37 | 3,200 | $27K | 13.1% |
| 6 | $8.38 | 736 |
| $6K |
| 3.0% |
| 7 | $8.39 | 864 | $7K | 3.5% |
| 8 | $8.40 | 1,531 | $13K | 6.3% |
| 9 | $8.41 | 2,300 | $19K | 9.4% |
| 10 | $8.42 | 999 | $8K | 4.1% |
| 11 | $8.43 | 21 | $177 | 0.1% |
| 12 | $8.44 | 100 | $844 | 0.4% |
| 13 | $8.45 | 1,500 | $13K | 6.2% |
| 14 | $8.46 | 300 | $3K | 1.2% |
| 15 | $8.47 | 376 | $3K | 1.6% |
| 16 | $8.48 | 400 | $3K | 1.7% |
| 17 | $8.49 | 200 | $2K | 0.8% |
| 18 | $8.50 | 491 | $4K | 2.0% |
| 19 | $8.51 | 200 | $2K | 0.8% |
| 20 | $8.52 | 200 | $2K | 0.8% |
| 21 | $8.54 | 100 | $854 | 0.4% |
| 22 | $8.28 | 400 | $3K | 1.6% |
| 23 | $8.29 | 1,500 | $12K | 6.1% |
| 24 | $8.30 | 2,000 | $17K | 8.1% |
| 25 | $8.31 | 600 | $5K | 2.4% |
| 26 | $8.32 | 1,500 | $12K | 6.1% |
| 27 | $8.33 | 36 | $300 | 0.1% |
| 28 | $8.34 | 100 | $834 | 0.4% |
| 29 | $8.35 | 2,102 | $18K | 8.6% |
| Total | $8.37 avg | 24,500 | $205K | 100% |
| Filing → |
| HALO | SELL | 2021-02-01 | $469K | — | Filing → |
| HALO | SELL | 2021-01-04 | $417K | — | Filing → |
| HALO | SELL | 2020-12-07 | $1.4M | — | Filing → |